Strongest — Major Business Impact
1
CMP
₹4,485.55
▲ +6.02%
52W High: ₹4,495 (today!)
52W Low: ₹3,089.70
Promoters: 52.90%
Institutions: 30.54%
Q4FY26: ~46% YoY growth in consumer businesses. Jewellery (Tanishq) +52%, Fragrances +30%, Women's Bags +47%, EyeCare +16%. 47 new stores added; total network 3,603 stores. Hits fresh 52-week high today.
Broad-based growth across ALL segments — jewellery, watches, fragrances, eyewear. Trading at its 52-week high is a very strong technical and fundamental signal. Tata Group stock with solid institutional backing.
52W Range: ₹3,089 — ₹4,495 | Currently at ALL-TIME HIGH territory
2
CMP
₹1,325.80
▲ +8.45%
52W High: ₹1,812.40
52W Low: ₹1,064.15
Promoters: 60.94%
Institutions: 36.68%
Record-high FY26 presales of ₹30,024 Cr — up 76% YoY. Q4FY26 presales ₹7,697 Cr (+10% YoY). Strong traction across Bengaluru, NCR, Mumbai, Hyderabad and Chennai.
Highest-ever annual presales driven by sustained end-user demand in premium residential. 76% YoY growth is exceptional for the sector. Still 27% below 52W peak — meaningful upside potential if momentum holds.
52W Range: ₹1,064 — ₹1,812 | Currently 27% below 52W high
3
CMP
₹152.85
▲ +5.23%
52W High: ₹202.65
52W Low: ₹134.35
Promoters: 51.88%
Institutions: 41.44%
Long-term charter party agreement with Alpha Gas (Greece) for LNG carrier 'Energy Fidelity' — 174,000 cu.m. capacity, advanced fuel-efficient two-stroke engine + air lubrication tech. Aligns with Maritime Amrit Kaal Vision 2047.
Strengthens India's LNG supply chain with a state-of-the-art vessel. Near-₹1 lakh Cr PSU with majority government ownership. Strong institutional backing (41%). 25% below 52W high — reasonable accumulation zone.
52W Range: ₹134 — ₹202 | Currently 25% below 52W high
4
CMP
₹3,710.00
▲ +6.94%
52W High: ₹3,970.00
52W Low: ₹2,362.00
Promoters: 50.27%
Institutions: 41.38%
Launches TVS Armado 200 three-wheeler in Indonesia — 197.75cc oil-cooled engine, 840 kg best-in-class payload, 2-metre cargo bed. Launch price IDR 34.9 million (~₹1.74 lakh). Targets Indonesia's booming logistics market.
Strategic international expansion into SE Asia's high-growth commercial vehicle market. Indonesia's logistics boom is a strong tailwind. Only 7% below 52W high — near-peak performance. Strong institutional holding (41%).
52W Range: ₹2,362 — ₹3,970 | Currently only 7% below 52W high
5
CMP
₹944.35
▲ +1.29%
52W High: ₹1,314.30
52W Low: ₹903.50 (yesterday!)
Promoters: 23.72%
Institutions: 71.76%
SPA signed to acquire 58.4% controlling stake in Kalinga Hospital, Bhubaneswar at equity value ₹300 Cr. 250-bed NABH-accredited hospital on 10 acres with 128-slice CT, 1.5T MRI, Cath Lab. Specialties: Cardiology, Neurology, Oncology, Orthopaedics. Deal closes in 4–6 weeks.
Running hospital acquisition adds immediate revenue and expands footprint to Odisha. 52W low was hit just yesterday — may signal a floor forming. Note: very low promoter holding (23.7%) but very high institutional confidence (71.8%).
52W Range: ₹903 — ₹1,314 | 52W low touched yesterday — watch for reversal
6
CMP
₹75.45
▲ +3.87%
52W High: ₹93.95
52W Low: ₹59.83
Promoters: 28.29%
Institutions: 14.22%
Subsidiary HTL bags ₹1,366 Cr orders from a Tier-1 customer for optical fibre cables — execution by December 2026. Largest single order value in today's entire list.
₹1,366 Cr order is massive relative to HFCL's ₹11,548 Cr market cap — exceptional revenue visibility. Optical fibre demand driven by India's BharatNet and 5G rollout. Low promoter holding (28%) is a caution flag. 20% below 52W high.
52W Range: ₹59 — ₹93 | Currently 20% below 52W high
Strong — Good Positives
7
CMP
₹1,341.50
▲ +0.90%
52W High: ₹1,369.95 (today!)
52W Low: ₹1,017.00
Promoters: 51.82%
Institutions: 41.63%
USFDA final approval for Dapagliflozin + Metformin HCl ER Tablets (4 strengths: 5/500mg, 5/1000mg, 10/500mg, 10/1000mg). RLD: Xigduo XR by AstraZeneca. US market size: $514 Mn (IQVIA). 180-day shared exclusivity. Launching immediately. Total: 579 ANDA approvals.
The COMBO tablet targeting $514 Mn US market with exclusivity is stronger than plain Dapagliflozin approvals. Aurobindo is one of the first ANDA applicants — exclusivity advantage. Also hits 52W high today. Total 579 ANDAs — one of India's largest pharma pipelines.
52W Range: ₹1,017 — ₹1,369 | Hits 52W high today — bullish signal
8
CMP
₹615.55
▲ +2.71%
52W High: ₹700.00
52W Low: ₹498.20
Promoters: 83.11%
Institutions: 5.55%
Q4FY26 revenue more than doubles to ₹3,552 Cr vs ₹1,587 Cr in Q4FY25. Retail segment +102% YoY, Franchise Operations +132% YoY, E-commerce +67% YoY. Store count now 78 — targeting 103 stores by FY27 end with 25 new openings planned.
Exceptional triple-digit growth across all channels. Franchise (+132%) and E-commerce (+67%) show the business model is scaling well beyond physical stores. Very high promoter holding (83%) signals strong ownership conviction. 12% below 52W high.
52W Range: ₹498 — ₹700 | Currently 12% below 52W high — room to recover
9
CMP
₹1,763.60
▲ +3.30%
52W High: ₹2,889.65
52W Low: ₹1,582.10
Promoters: 82.50%
Institutions: 15.02%
Price hike of up to 1% across entire car portfolio from May 2026, attributed to rising input costs. Quantum varies by model and variant. Company had been absorbing costs — now passing on a portion.
Price hike signals pricing power and margin protection ability — positive for profitability. Very high promoter stake (82.5%) shows parent confidence. However, 39% below 52W high shows significant underperformance from peak — buyer beware at current levels.
52W Range: ₹1,582 — ₹2,889 | 39% below 52W high — significant correction
10
CMP
₹884.35
▲ +1.22%
52W High: ₹1,059.00
52W Low: ₹813.00
Promoters: 75.00%
Institutions: 18.15%
USFDA final approval for Dapagliflozin Tablets 5mg and 10mg (RLD: Farxiga by AstraZeneca). 180-day shared exclusivity. Manufactured at Ahmedabad SEZ. Total: 436 approvals, 505 ANDAs filed since FY2003-04.
Strong US pharma approval with exclusivity. Very high promoter holding (75%) is a comfort. However, this is a shared generic race with Lupin and Biocon also getting the same approval — exclusivity revenue is split. 16% below 52W high.
52W Range: ₹813 — ₹1,059 | Currently 16% below 52W high
11
CMP
₹2,334.95
▲ +1.67%
52W High: ₹2,376.00
52W Low: ₹1,838.65
Promoters: 46.89%
Institutions: 47.07%
USFDA approval for Dapagliflozin Tablets 5mg and 10mg — bioequivalent to Farxiga. Same drug approved simultaneously for Zydus and Biocon. Shared 180-day exclusivity among all three companies.
Good approval but revenue upside is shared across three Indian companies. Only 2% below 52W high — already near peak valuation. Very low trading volume today (only 150 shares) — thin market participation. Strong institutional holding (47%) is a positive.
52W Range: ₹1,838 — ₹2,376 | Only 2% below 52W high — near peak
12
CMP
₹345.50
▲ +1.57%
52W High: ₹424.95
52W Low: ₹303.85
Promoters: 54.45%
Institutions: 29.10%
Subsidiary Biocon Pharma gets USFDA approval for Dapagliflozin Tablets 5mg and 10mg for type 2 diabetes and heart failure risk reduction. Extends Biocon's diabetes portfolio — oral solid dosage, biosimilar insulin and complex GLP-1 peptides.
Same Dapagliflozin as Lupin and Zydus — exclusivity is shared. However, Biocon's broader integrated diabetes portfolio (insulin + GLP-1 + oral) is a genuine differentiator. 19% below 52W high. Good promoter holding (54.4%).
52W Range: ₹303 — ₹424 | Currently 19% below 52W high
13
CMP
₹259.05
▲ +5.30%
52W High: ₹328.30
52W Low: ₹208.90
Promoters: 28.87%
Institutions: 30.57%
Client base grows 20.5% YoY to 37.39 million in March 2026. Overall ADTO (notional) jumps 37.3% YoY to ₹49,95,700 Cr. F&O ADTO: ₹48,03,200 Cr. Cash segment ADTO: ₹6,900 Cr. Commodity ADTO: ₹1,85,500 Cr.
Strong growth in client base and trading volumes. However, F&O turnover is 96% of total — heavy concentration risk if SEBI tightens F&O regulations further. Low promoter holding (29%) is a watch point. 21% below 52W high.
52W Range: ₹208 — ₹328 | 21% below 52W high | Regulatory risk watch
Moderate — Positive but Limited Scale
14
CMP
₹337.15
▲ +9.82%
52W High: ₹594.10
52W Low: ₹270.00
Promoters: 64.06%
Institutions: 9.16%
Signs franchise agreement with Hilton to develop 125 Hampton by Hilton hotels in India. Strategic partnership to scale mid-market hospitality brand. Financial details — capex, timeline, revenue targets — not yet disclosed.
Best single-day gainer today (+9.82%) but the Hilton deal has no disclosed financials — no investment size, no launch timeline. Ranked moderate because intent is exciting but execution details are missing. Only 4,239 shares traded — very low liquidity. 43% below 52W high.
52W Range: ₹270 — ₹594 | 43% below 52W high | Low liquidity caution
15
CMP
₹4,340.00
▲ +9.53%
52W High: ₹5,341.30
52W Low: ₹1,513.05
Promoters: 58.97%
Institutions: 1.25%
March 2026 commercial vehicle sales up 12.4% YoY to 2,393 units vs 2,129 units. Production up 3.6% YoY to 1,652 units. 64 units exported. Strong monthly data triggers sharp +9.53% rally.
Solid sales growth but production growth (3.6%) lagged sales growth (12.4%) — possible inventory drawdown. Very low institutional holding (only 1.25%) means low analyst coverage and higher volatility. 52W range is extreme — from ₹1,513 to ₹5,341 — very high-risk stock. 19% below 52W high.
52W Range: ₹1,513 — ₹5,341 | Extreme volatility | Very low inst. holding
16
CMP
₹323.60
▲ +4.95%
52W High: ₹374.00
52W Low: ₹248.75
Promoters: 61.11%
Institutions: 15.95%
Q4FY26 value of area sold more than doubles to ₹1,289.70 Cr vs ₹574.73 Cr. 665 units booked vs 357 in Q3FY26. 849 units launched across Bhiwadi, Gurugram, Pune and Chennai. FY26 full-year sales ₹2,421 Cr vs ₹1,937 Cr in FY25.
Strong Q4 with broad geographic expansion into new markets. Consistent growth trajectory — FY26 full year also healthy at +25% YoY. Good promoter holding (61%). Only 13% below 52W high — relatively resilient small cap.
52W Range: ₹248 — ₹374 | 13% below 52W high | Healthy small cap
17
CMP
₹142.10
▲ +8.56%
52W High: ₹253.00
52W Low: ₹107.10
Promoters: 72.82%
Institutions: 1.93%
LoA as sub-contractor from Solarium Green Energy for 50 MWac Solar PV EPC project in Maharashtra under MAHAGENCO. Total order value: ~₹165 Cr (excl. GST). Accepted April 7, 2026. Excludes 3-year O&M services.
₹165 Cr order is very significant vs ₹867 Cr market cap — strong revenue visibility. However, sub-contractor status means margin and execution risk. 44% below 52W high. Very low institutional holding (1.93%) and high promoter control (72.8%).
52W Range: ₹107 — ₹253 | 44% below 52W high | Sub-contractor risk
SEBI Regulatory Disclaimer — Please Read Carefully Before Acting
This article is published strictly for informational and educational purposes only. It does not constitute investment advice, a research report, solicitation, or an offer to buy or sell any securities. The publisher is NOT registered as a Research Analyst under the SEBI (Research Analysts) Regulations, 2014.
All price data, market capitalisation, shareholding patterns, 52-week high/low data, and corporate announcements are sourced from publicly available BSE/NSE disclosures and are believed accurate at time of compilation. They are subject to change without notice and may be inaccurate by the time of reading.
Stock market investments are subject to market risks. Past performance is NOT indicative of future results. Micro-cap and small-cap stocks carry significantly higher risk due to low liquidity, limited disclosures, and potential for price manipulation. Penny stocks and BSE Group B stocks carry especially elevated risk — exercise extreme caution.
The 180-day shared drug exclusivity mentioned for Dapagliflozin approvals (Zydus, Lupin, Biocon) applies simultaneously to all three companies — investors should NOT assume exclusive revenue for any single company.
Investors are strongly advised to conduct their own independent due diligence and consult a SEBI-registered investment advisor before making any investment decisions. For market-related grievances, contact SEBI at scores.sebi.gov.in | Helpline: 1800 266 7575 / 1800 22 7575.